Your browser is no longer supported. Please, upgrade your browser.
Settings
STML Stemline Therapeutics, Inc. daily Stock Chart
STML [NASD]
Stemline Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.58 Insider Own7.90% Shs Outstand47.68M Perf Week3.32%
Market Cap636.90M Forward P/E- EPS next Y-0.85 Insider Trans-8.00% Shs Float48.07M Perf Month0.37%
Income-70.70M PEG- EPS next Q-0.37 Inst Own78.80% Short Float6.82% Perf Quarter101.83%
Sales47.00M P/S13.55 EPS this Y39.10% Inst Trans-2.87% Short Ratio1.96 Perf Half Y18.65%
Book/sh3.10 P/B3.92 EPS next Y35.60% ROA-41.40% Target Price17.64 Perf Year-9.93%
Cash/sh2.90 P/C4.18 EPS next 5Y- ROE-48.10% 52W Range3.21 - 18.22 Perf YTD14.30%
Dividend- P/FCF- EPS past 5Y3.90% ROI-48.50% 52W High-34.50% Beta1.72
Dividend %- Quick Ratio7.40 Sales past 5Y164.30% Gross Margin88.40% 52W Low271.81% ATR0.37
Employees104 Current Ratio7.40 Sales Q/Q78.00% Oper. Margin- RSI (14)73.78 Volatility1.20% 1.14%
OptionableYes Debt/Eq0.00 EPS Q/Q38.80% Profit Margin- Rel Volume0.40 Prev Close12.15
ShortableYes LT Debt/Eq0.00 EarningsMar 16 BMO Payout- Avg Volume1.67M Price11.94
Recom1.80 SMA20-0.58% SMA5048.78% SMA20035.36% Volume286,531 Change-1.77%
May-05-20Downgrade Alliance Global Partners Buy → Neutral $14.50 → $12.50
Jan-21-20Reiterated H.C. Wainwright Buy $35 → $20
Dec-24-19Initiated Cantor Fitzgerald Overweight $18
Nov-25-19Initiated Alliance Global Partners Buy $21
Aug-02-19Upgrade Wedbush Neutral → Outperform
May-13-19Downgrade Wedbush Outperform → Neutral $18
Dec-11-18Initiated JP Morgan Overweight $17
Nov-26-18Initiated Piper Jaffray Overweight $20
Jun-12-18Initiated ROTH Capital Buy $30
Nov-01-17Reiterated H.C. Wainwright Buy $34 → $38
Feb-06-17Reiterated Wedbush Outperform $19 → $11
Mar-15-16Reiterated Wedbush Outperform $19 → $15
Apr-27-15Initiated H.C. Wainwright Buy $38
Apr-22-15Resumed Jefferies Buy
Jan-26-15Reiterated ROTH Capital Buy $62 → $50
Oct-30-13Reiterated Aegis Capital Buy $40 → $70
May-28-20 10:11AM  
May-21-20 02:10PM  
May-19-20 06:06PM  
12:23PM  
10:14AM  
May-18-20 05:30PM  
02:00PM  
May-16-20 03:00PM  
May-15-20 02:40PM  
02:39PM  
01:20PM  
May-14-20 05:32PM  
05:30PM  
09:33AM  
May-13-20 12:40PM  
May-12-20 06:00PM  
09:51AM  
May-11-20 03:30PM  
01:40PM  
06:29AM  
May-08-20 12:33PM  
May-07-20 11:40AM  
10:40AM  
May-05-20 11:35PM  
07:57PM  
02:45PM  
02:23PM  
10:45AM  
May-04-20 05:00PM  
03:35PM  
02:08PM  
01:44PM  
12:28PM  
12:15PM  
11:40AM  
11:22AM  
10:58AM  
07:00AM  
May-01-20 01:08PM  
12:30PM  
Apr-13-20 01:44PM  
Mar-30-20 05:15PM  
Mar-17-20 09:24AM  
Mar-13-20 06:05PM  
04:45PM  
Mar-11-20 04:05PM  
Feb-26-20 07:30AM  
Feb-04-20 04:00PM  
Jan-20-20 12:48PM  
Jan-14-20 07:55AM  
Jan-13-20 04:15PM  
Jan-08-20 04:15PM  
Dec-26-19 10:10AM  
Dec-10-19 02:44PM  
08:00AM  
Dec-06-19 06:30PM  
07:00AM  
Nov-29-19 01:05PM  
Nov-17-19 12:06AM  
Nov-11-19 05:50AM  
Nov-08-19 08:14AM  
Nov-07-19 04:57PM  
Nov-06-19 09:15AM  
Nov-05-19 04:22PM  
Oct-30-19 11:20AM  
Oct-22-19 03:27PM  
Oct-08-19 07:30AM  
Oct-01-19 07:30AM  
Sep-27-19 07:30AM  
Sep-26-19 04:01PM  
Sep-19-19 08:49AM  
Sep-18-19 09:32AM  
Sep-02-19 11:39AM  
Aug-27-19 07:11AM  
Aug-16-19 11:15PM  
Aug-14-19 08:14AM  
Aug-12-19 05:06AM  
Aug-09-19 04:00PM  
Aug-08-19 10:23PM  
Aug-07-19 04:25PM  
Aug-06-19 07:30AM  
Aug-02-19 11:19AM  
08:25AM  
07:00AM  
Jul-29-19 07:00AM  
Jul-15-19 03:29PM  
Jul-08-19 05:50PM  
Jun-28-19 08:00AM  
Jun-19-19 10:39AM  
Jun-17-19 07:30AM  
Jun-13-19 07:30AM  
Jun-03-19 01:40PM  
07:30AM  
May-26-19 11:25PM  
May-20-19 07:00AM  
May-16-19 07:00AM  
May-13-19 10:02AM  
May-10-19 06:46PM  
07:45AM  
06:40AM  
Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Francomano RobertChief Commercial OfficerMay 04Sale11.512723,131197,658May 06 09:31 PM
Bergstein IvanChief Executive OfficerApr 15Sale4.8853,618261,6562,804,336Apr 20 06:07 AM
Gionco DavidChief Accounting OfficerApr 01Sale4.7911,52455,200282,878Apr 03 09:31 PM
Gionco DavidChief Accounting OfficerMar 16Sale3.882,84911,054316,885Mar 20 09:30 PM
Gionco DavidChief Accounting OfficerMar 10Sale4.928,84643,522319,734Mar 13 09:31 PM
Hoberman KennethChief Operating OfficerMar 10Sale4.9116,70482,017771,764Mar 13 09:31 PM
Bergstein IvanChief Executive OfficerMar 10Sale4.9236,542179,7872,857,954Mar 13 09:31 PM
Bergstein IvanChief Executive OfficerMar 09Sale5.0920,909106,4272,894,496Mar 13 09:31 PM
Francomano RobertChief Commercial OfficerMar 09Sale5.001,2666,330197,930Mar 13 09:31 PM
Hoberman KennethChief Operating OfficerMar 09Sale5.089,48748,194788,468Mar 13 09:31 PM
Gionco DavidChief Accounting OfficerMar 09Sale5.085,01125,456328,580Mar 13 09:31 PM
Bergstein IvanChief Executive OfficerFeb 25Sale6.4224,642158,2022,915,405Feb 28 09:32 PM
Gionco DavidChief Accounting OfficerFeb 25Sale6.439,14758,815333,591Feb 28 09:32 PM
Hoberman KennethChief Operating OfficerFeb 25Sale6.4211,54774,132797,955Feb 28 09:31 PM
Francomano RobertChief Commercial OfficerFeb 07Sale6.725,06434,03093,257Feb 14 09:29 PM
Hoberman KennethChief Operating OfficerJan 22Sale7.0222,139155,416601,085Jan 24 09:31 PM
Hoberman KennethChief Operating OfficerJan 08Sale10.3713,228137,174623,224Jan 10 09:16 PM
Francomano RobertChief Commercial OfficerDec 27Sale10.481161,21698,321Jan 03 05:17 PM
Hoberman KennethChief Operating OfficerDec 27Sale10.482,02221,191636,452Jan 03 05:19 PM
Gionco DavidChief Accounting OfficerDec 27Sale10.481972,065235,421Jan 03 05:18 PM
Bergstein IvanChief Executive OfficerDec 27Sale10.482,44625,6342,514,773Jan 03 05:18 PM
Bergstein IvanChief Executive OfficerDec 26Sale10.7518,744201,4982,517,219Jan 03 05:18 PM
Gionco DavidChief Accounting OfficerDec 26Sale10.751,51116,243235,618Jan 03 05:18 PM
Hoberman KennethChief Operating OfficerDec 26Sale10.7515,494166,561638,474Jan 03 05:19 PM
Francomano RobertChief Commercial OfficerDec 26Sale10.758939,60098,437Jan 03 05:17 PM
Francomano RobertChief Commercial OfficerDec 24Sale10.971,41215,49099,330Jan 03 05:17 PM
Hoberman KennethChief Operating OfficerDec 24Sale10.9724,477268,513653,968Jan 03 05:19 PM
Gionco DavidChief Accounting OfficerDec 24Sale10.972,38826,196237,129Jan 03 05:18 PM
Bergstein IvanChief Executive OfficerDec 24Sale10.9729,613324,8552,535,963Jan 03 05:18 PM
Bergstein IvanChief Executive OfficerDec 23Sale10.585,22555,2812,565,576Jan 03 05:18 PM
Gionco DavidChief Accounting OfficerDec 23Sale10.584214,454239,517Jan 03 05:18 PM
Hoberman KennethChief Operating OfficerDec 23Sale10.584,31945,695678,445Jan 03 05:19 PM
Francomano RobertChief Commercial OfficerDec 23Sale10.582492,634100,742Jan 03 05:17 PM
Forman Alan SDirectorDec 04Buy9.731,0009,73088,298Dec 06 07:51 PM
Forman Alan SDirectorDec 02Buy10.291,00010,29087,298Dec 04 09:36 PM
Bergstein IvanChief Executive OfficerAug 14Sale14.7335,010515,6972,570,801Aug 16 09:30 PM
Bergstein IvanChief Executive OfficerJun 26Sale14.7716,994251,0012,605,811Jun 28 05:16 PM
Hoberman KennethChief Operating OfficerJun 26Sale14.7712,508184,743682,764Jun 28 05:17 PM
Hoberman KennethChief Operating OfficerJun 25Sale15.0725,500384,285695,272Jun 28 05:17 PM
Bergstein IvanChief Executive OfficerJun 25Sale15.1028,500430,3502,622,805Jun 28 05:16 PM
Bergstein IvanChief Executive OfficerJun 24Sale15.4910,822167,6332,651,305Jun 28 05:16 PM
Hoberman KennethChief Operating OfficerJun 24Sale15.499,107141,067720,772Jun 28 05:17 PM